Thai Breast Disease Society,
One year of adjuvant everolimus + ET did not improve overall outcomes. Subset analysis suggests mTOR inhibition as a possible…
Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer
Overview of attention for article published in Journal of Clinical Oncology, June 2024
Altmetric Badge
Readers on
- mendeley
- 19 Mendeley